The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system

Citation for published version:
Tai, H-C, Serrano-Pozo, A, Hashimoto, T, Frosch, MP, Spires-Jones, TL & Hyman, BT 2012, 'The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system' American Journal Of Pathology, vol 181, no. 4, pp. 1426-35. DOI: 10.1016/j.ajpath.2012.06.033

Digital Object Identifier (DOI):
10.1016/j.ajpath.2012.06.033

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
American Journal Of Pathology

Publisher Rights Statement:
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved. This document may be redistributed and reused, subject to certain conditions.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
The Synaptic Accumulation of Hyperphosphorylated Tau Oligomers in Alzheimer Disease Is Associated With Dysfunction of the Ubiquitin-Proteasome System

Hwan-Ching Tai,* Alberto Serrano-Pozo,* Tadafumi Hashimoto,* Matthew P. Frosch,† Tara L. Spires-Jones,* and Bradley T. Hyman*

From the MassGeneral Institute of Neurodegenerative Disease* and the C.S. Kubik Laboratory for Neuropathology,† Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts

In Alzheimer disease (AD), deposition of neurofibrillary tangles and loss of synapses in the neocortex and limbic system each correlate strongly with cognitive impairment. Tangles are composed of misfolded hyperphosphorylated tau proteins; however, the link between tau abnormalities and synaptic dysfunction remains unclear. We examined the location of tau in control and AD cortices using biochemical and morphologic methods. We found that, in addition to its well-described axonal localization, normal tau is present at both presynaptic and postsynaptic terminals in control human brains. In AD, tau becomes hyperphosphorylated and misfolded at both presynaptic and postsynaptic terminals, and this abnormally posttranslationally modified tau is enriched in synaptonemal fractions. Synaptic tau seems to be hyperphosphorylated and ubiquitinated, and forms stable oligomers resistant to SDS denaturation. The accumulation of hyperphosphorylated tau oligomers at human AD synapses is associated with increased ubiquitinated substrates and increased proteasome components, consistent with dysfunction of the ubiquitin-proteasome system. Our findings suggest that synaptic hyperphosphorylated tau oligomers may be an important mediator of the proteotoxicity that disrupts synapses in AD. (Am J Pathol 2012, 181:1426–1435; http://dx.doi.org/10.1016/j.ajpath.2012.06.033)

Alzheimer disease (AD) is the most common neurodegenerative disorder in the elderly, and affects primarily the neocortex and the limbic system, with complex pathophysiologic features that include tau inclusions (neurofibrillary tangles, neuropil threads, and dystrophic neurites), β-amyloid inclusions (plaques and cerebral amyloid angiopathy), loss of neurons and synapses, astrogliosis, microglial activation, and inflammation.1,2 Among these features, synaptic loss3,4 and neurofibrillary tangle deposition5,6 seem to best correlate with cognitive decline.

Neurofibrillary and synaptic loss are correlated in clinicopathologic studies of AD7; however, whether this is a co-occurrence of parallel pathologic processes or synaptic loss is more directly related to alterations in tau biology is uncertain.8,9 We, therefore, used new biochemical and morphologic techniques to address the issue of tau protein accumulation in synapses in the adult human brain and in AD.

Normal tau is an abundant microtubule-associated protein that has been described as predominantly localized in axons in mature neurons.10 In AD, abnormally folded and hyperphosphorylated tau (p-tau) accumulates in axons, dendrites, and somas.11,12 In contrast to these long-held generalizations, recent reports have suggested that tau is also normally present in dendritic spines, where it interacts with postsynaptic density (PSD) proteins such as Fyn kinase.13

We hypothesized that tau may pathologically accumulate at synaptic sites in AD because it has been recently suggested that tau can be present in postsynaptic locales in normal mice,13 ubiquitinated tau accumulates in the brain in AD,14,15 and a major site of protein ubiquitination and proteasome-mediated degradation is at presynaptic and postsynaptic structures.16,17 By isolating synaptic terminals, we observed that, in control brains, tau is present at both presynaptic and postsynaptic ter-
minals. In contrast, in synaptoneurosomes isolated from brains in AD, p-tau can form stable SDS-resistant oligomers that accumulate on both sides of the synapse, showing synaptic enrichment when compared with the cytoplasm. The accumulation of p-tau at the synapse mirrors the accumulation of ubiquitinated proteins in the same fraction, as well as the accumulation of proteasomes and related chaperones, which suggests that tau aggregates are associated with impaired proteolysis mediated by the ubiquitin-proteasome system.18

Materials and Methods

Reagents

Protease inhibitor (cOmplete tablet) was purchased from Roche Applied Science (Roche Diagnostics Corp., Indianapolis, IN). Phosphatase inhibitor cocktails 2 and 3 were purchased from Sigma-Aldrich Corp. (St. Louis, MO) and used in a 1:1 combination. Mouse monoclonal antibodies PHF1 (pS396/pS404 tau), CP13 (pS202 tau), and DA9 (total tau) were gifts of Peter Davies (Albert Einstein College of Medicine, Bronx, NY). Rabbit anti-total tau (A20024) was purchased from Dako Denmark A/S (Glostrup, Denmark); rabbit anti-PSD95(20S subunit, PW8110), and mouse anti-Rpt1 (26S subunit, PW8852) from Enzo Clinical Laboratories, Inc. (Farmingdale, NY).

Table 1. Characteristics of Control and AD-Affected Brains Used in Quantitative Studies

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Clinical Diagnosis</th>
<th>Disease Duration (years)</th>
<th>ApoE Genotype</th>
<th>PMI (hours)</th>
<th>Braak Stage</th>
<th>Experiment</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1</td>
<td>89</td>
<td>F</td>
<td>Control</td>
<td>NA</td>
<td>2/3</td>
<td>13</td>
<td>2</td>
<td>Figure 4</td>
</tr>
<tr>
<td>C2</td>
<td>91</td>
<td>F</td>
<td>Control</td>
<td>NA</td>
<td>3/3</td>
<td>19</td>
<td>2</td>
<td>Figure 4</td>
</tr>
<tr>
<td>C3</td>
<td>71</td>
<td>M</td>
<td>Control</td>
<td>NA</td>
<td>NA</td>
<td>5</td>
<td>0</td>
<td>Figure 4</td>
</tr>
<tr>
<td>C4</td>
<td>87</td>
<td>M</td>
<td>Control</td>
<td>NA</td>
<td>NA</td>
<td>36</td>
<td>1</td>
<td>Figure 4</td>
</tr>
<tr>
<td>C5</td>
<td>80</td>
<td>F</td>
<td>Control</td>
<td>NA</td>
<td>2/4</td>
<td>54</td>
<td>1</td>
<td>Figure 7</td>
</tr>
<tr>
<td>C6</td>
<td>76</td>
<td>M</td>
<td>Control</td>
<td>NA</td>
<td>3/4</td>
<td>48</td>
<td>1</td>
<td>Figure 7</td>
</tr>
<tr>
<td>C7</td>
<td>85</td>
<td>M</td>
<td>Control</td>
<td>NA</td>
<td>3/3</td>
<td>24</td>
<td>2</td>
<td>Figure 7</td>
</tr>
<tr>
<td>C8</td>
<td>57</td>
<td>F</td>
<td>Control</td>
<td>NA</td>
<td>3/3</td>
<td>13</td>
<td>0</td>
<td>Figure 7</td>
</tr>
<tr>
<td>C9</td>
<td>74</td>
<td>F</td>
<td>Control</td>
<td>NA</td>
<td>3/3</td>
<td>24</td>
<td>1</td>
<td>Figure 7</td>
</tr>
<tr>
<td>C10</td>
<td>88</td>
<td>F</td>
<td>Control</td>
<td>NA</td>
<td>3/3</td>
<td>20</td>
<td>2</td>
<td>Figure 7</td>
</tr>
<tr>
<td>AD1</td>
<td>83</td>
<td>F</td>
<td>AD</td>
<td>NA</td>
<td>13</td>
<td>12</td>
<td>5</td>
<td>Figure 4</td>
</tr>
<tr>
<td>AD2</td>
<td>82</td>
<td>M</td>
<td>AD</td>
<td>NA</td>
<td>6</td>
<td>3/4</td>
<td>7</td>
<td>Figure 4</td>
</tr>
<tr>
<td>AD3</td>
<td>91</td>
<td>F</td>
<td>AD</td>
<td>14</td>
<td>3/4</td>
<td>9</td>
<td>5</td>
<td>Figure 4</td>
</tr>
<tr>
<td>AD4</td>
<td>95</td>
<td>M</td>
<td>AD</td>
<td>NA</td>
<td>3/3</td>
<td>11</td>
<td>6</td>
<td>Figure 4</td>
</tr>
<tr>
<td>AD5</td>
<td>85</td>
<td>F</td>
<td>AD</td>
<td>4</td>
<td>3/4</td>
<td>10</td>
<td>5</td>
<td>Figure 5</td>
</tr>
<tr>
<td>AD6</td>
<td>73</td>
<td>F</td>
<td>AD</td>
<td>19</td>
<td>3/3</td>
<td>14</td>
<td>5</td>
<td>Figure 5</td>
</tr>
<tr>
<td>AD7</td>
<td>84</td>
<td>F</td>
<td>AD</td>
<td>16</td>
<td>3/4</td>
<td>12</td>
<td>5</td>
<td>Figure 5</td>
</tr>
<tr>
<td>AD8</td>
<td>65</td>
<td>M</td>
<td>AD</td>
<td>8</td>
<td>3/3</td>
<td>21</td>
<td>5</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD9</td>
<td>84</td>
<td>F</td>
<td>AD</td>
<td>7</td>
<td>3/3</td>
<td>7</td>
<td>6</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD10</td>
<td>75</td>
<td>F</td>
<td>AD</td>
<td>5</td>
<td>3/3</td>
<td>26</td>
<td>6</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD11</td>
<td>92</td>
<td>F</td>
<td>AD</td>
<td>9</td>
<td>3/3</td>
<td>4</td>
<td>6</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD12</td>
<td>93</td>
<td>M</td>
<td>AD</td>
<td>17</td>
<td>3/3</td>
<td>6</td>
<td>5</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD13</td>
<td>74</td>
<td>M</td>
<td>AD</td>
<td>11</td>
<td>3/3</td>
<td>15</td>
<td>5</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD14</td>
<td>92</td>
<td>M</td>
<td>AD</td>
<td>22</td>
<td>4/4</td>
<td>12</td>
<td>5</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD15</td>
<td>68</td>
<td>F</td>
<td>AD</td>
<td>11</td>
<td>4/4</td>
<td>20</td>
<td>5</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD16</td>
<td>80</td>
<td>F</td>
<td>AD</td>
<td>12</td>
<td>4/4</td>
<td>11</td>
<td>6</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD17</td>
<td>71</td>
<td>F</td>
<td>AD</td>
<td>17</td>
<td>4/4</td>
<td>14</td>
<td>6</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD18</td>
<td>74</td>
<td>M</td>
<td>AD</td>
<td>17</td>
<td>4/4</td>
<td>20</td>
<td>5</td>
<td>Figures 7, 8</td>
</tr>
<tr>
<td>AD19</td>
<td>89</td>
<td>M</td>
<td>AD</td>
<td>10</td>
<td>4/4</td>
<td>10</td>
<td>5</td>
<td>Figures 7, 8</td>
</tr>
</tbody>
</table>

F = female; M = male; AD = Alzheimer disease; NA = not applicable or not available; PMI = postmortem interval.

Human Subjects

Brains from human subjects with a diagnosis of AD or no cognitive deficits were obtained through the Massachusetts Alzheimer’s Disease Research Center and Massachusetts General Hospital Neuropathology Department. All donor tissue was obtained in accord with local and national institutional review board regulations. Characteristics of controls and subjects with AD used for quantitative analyses are given in Table 1.

Subcellular Fractionation and Protein Extraction

Cortical gray matter (200 to 300 mg) taken from frozen human brains was gently ground in a Potter-Elvehjem homogenizer with 1.5 mL ice-cold buffer A (25 mmol/L HEPES [pH 7.5], 120 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl₂, and 2 mmol/L CaCl₂) supplemented with 2 mmol/L dithiothreitol (DTT), protease inhibitors, and phosphatase inhibitors. The homogenate was passed through two layers of 80-μm nylon filters (Millipore) to
remove tissue debris, and a 200-µL aliquot was saved. The saved aliquot was mixed with 200 µL and 70 µL 10% SDS, passed through a 27-gauge needle, and boiled for 5 minutes to prepare the total extract.

To prepare filtered synaptoneurosomes as described by Hollingsworth et al, the remainder of the homogenate was passed through a 5-µm Supor membrane filter (Pall Corp., Port Washington, NY) to remove large organelles and nuclei, and centrifuged at 1000 × g for 5 minutes. The pellet was washed once with buffer A and centrifuged again, yielding the synaptoneurosome pellet. Supernatant from the first centrifugation was clarified via centrifugation at 100,000 × g for 1 hour to obtain the cytosol fraction. Cytosolic extract was prepared by adding 1.5% SDS and boiling for 5 minutes. Synaptoneurosome pellets were extracted using 0.5 mL buffer B (50 mmol/L Tris [pH 7.5], 1.5% SDS, and 2 mmol/L DTT), and were boiled for 5 minutes.

**Sucrose Flotation Gradient**

Flotation sucrose gradient for isolating synaptic terminals was modified from previously published procedures. Ice-cold sucrose solutions of 0.3, 0.93, and 1.2 mol/L were prepared using 10 mmol/L HEPES (pH 7.5). The synaptoneurosome pellet was resuspended in 1.2 mmol/L sucrose and transferred to a centrifuge tube, and then overlayed with 1.2, 0.93, and 0.3 mol/L sucrose to form a three-layer discontinuous gradient. After centrifugation at 60,000 × g for 2 hours, synaptic terminals were collected from the 0.93/1.2-mol/L interface, and myelin from the 0.3/0.93-mol/L interface, and both were diluted with water to about 0.3 mol/L final sucrose concentration. The pellet was also resuspended in 0.3 mol/L sucrose. All three fractions were centrifuged at 20,000 × g for 20 minutes, and the pellets were extracted using buffer B and boiled for 5 minutes.

**Triton Extraction**

The synaptoneurosome pellet was resuspended in ice-cold buffer C [50 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 2% Triton X-100, and protease inhibitors]. After 20 minutes of incubation in a rotating tube, the mixture was centrifuged at 100,000 × g for 1 hour. The collected supernatant was supplemented with 1% SDS and boiled for 5 minutes. The pellet was extracted using buffer B and boiled for 5 minutes.

**Gel Electrophoresis and Immunoblotting**

SDS-denatured protein extracts were clarified via centrifugation at 20,000 × g for 15 minutes, followed by biocinchoninic acid assays (Pierce Protein Biology, Fisher Scientific, Inc., Rockford, IL) to determine protein concentrations. Extracts were boiled again for 3 minutes after adding 5X sample buffer (250 mmol/L Tris [pH 7.5], 5% SDS, 400 mmol/L DTT, 50% glycerol, and 0.2% Orange G). Samples were resolved via SDS-PAGE using Bis-Tris 4% to 12% gels (Invitrogen Corp., Carlsbad, CA), and were transferred to low-fluorescence polyvinylidene difluoride or nitrocellulose membranes for immunoblotting, detected using an Odyssey laser scanner (LI-COR Biosciences, Inc., Lincoln, NE). Blocking buffer, stripping buffer, and secondary antibodies were purchased from LI-COR, and were used according to the manufacturer's protocols.

**Ubiquitin Pull-Down and Tau Immunoprecipitation**

Synaptoneurosome pellets were resuspended in buffer D (20 mmol/L Tris [pH 7.5], 150 mmol/L NaCl, 0.2% SDS, and 4 mmol/L DTT), boiled for 5 minutes, and cleared via centrifugation at 15,000 × g for 10 minutes. The supernatant was mixed with an equal volume of buffer E (20 mmol/L Tris [pH 7.5], 150 mmol/L NaCl, 2% Triton X-100, 0.5% SDS, and 5% glycerol). The mixture was incubated at 4°C for 1 hour, followed by addition of 5X sample buffer (250 mmol/L Tris [pH 7.5], 5% SDS, 400 mmol/L DTT, 50% glycerol, and 0.2% Orange G). Samples were resolved via SDS-PAGE using Bis-Tris 4% to 12% gels (Invitrogen Corp., Carlsbad, CA), and were transferred to low-fluorescence polyvinylidene difluoride or nitrocellulose membranes for immunoblotting, detected using an Odyssey laser scanner (LI-COR Biosciences, Inc., Lincoln, NE). Blocking buffer, stripping buffer, and secondary antibodies were purchased from LI-COR, and were used according to the manufacturer's protocols.

**Figure 1.** Total SDS-soluble extracts of human AD cortices show p-tau (detected using PHF1 and CP13) accumulation compared with controls. Actin serves as loading control.

**Figure 2.** A: Synaptoneurosomes from human cortices examined under electron microscopy show well-preserved synaptic structures (arrows). No protein fibrils were observed in control or AD samples. B: In AD-affected brains, p-tau oligomers (detected using PHF1 and CP13) accumulate in the synaptoneurosome (S) but not in the cytosol (C). Synaptoplathrin (Synph) and PSD95 serve as synaptic markers. Images are representative of three independent experiments.
and 1% sodium deoxycholate) to neutralize SDS. The mixture was pre-cleared via incubation using Protein G Sepharose (GE Healthcare, Pittsburg, PA) at 4°C for 1 hour, followed by overnight incubation with SSa UIM agarose conjugate (UW9820; Enzo Clinical Laboratories) or protein G sepharose (control). After centrifugation at 1000 x g for 2 minutes, the supernatant was collected as the flow-through fraction. The resin was washed three times with cold buffer F (20 mmol/L Tris [pH 7.5], 150 mmol/L NaCl, and 1% Triton X-100) and boiled for 5 minutes with 1.5X SDS-PAGE sample buffer to elute captured ubiquitinated proteins. In immunoprecipitation experiments, the pre-cleared extract was incubated overnight at 4°C with rabbit anti–total tau or anti-Myc (control), followed by incubation with protein G sepharose for 2 hours. After centrifugation at 1000 x g for 2 minutes, the supernatant was collected as the flow-through fraction. The resin was washed three times with cold buffer F and boiled for 5 minutes with 1.5X SDS-PAGE sample buffer to elute captured proteins. Western blots of immunoprecipitation proteins were detected via enhanced chemiluminescence using TrueBlot Ultra anti-mouse horseradish peroxidase conjugate (eBioscience, Inc., San Diego, CA) or Clean-Blot horseradish peroxidase conjugate (against rabbit primary antibodies; Pierce) to minimize signals from denatured IgG.

Immunostaining of Synaptoneurosomes

Synaptoneurosome pellets were resuspended in ice-cold buffer A, passed through 27-gauge needles, and mixed with an equal volume of 2% paraformaldehyde in PBS-MC (1 mmol/L MgCl2 and 1 mmol/L CaCl2) in Lab-Tek II CC2 pre-coated chamber slides (Nunc, Rochester, NY). After 10 minutes of settling at 4°C, synaptoneurosomes became fixed and attached to the glass surface, and were washed three times using PBS-MC (room temperature from this point on). Synaptoneurosomes were permeabilized using 0.05% Triton X-100 in PBS-MC with 3% bovine serum albumin (BSA), and washed three times. Slides were blocked using 4% normal goat serum and 3% BSA in PBS-MC for 30 minutes and then incubated with primary antibodies diluted in PBS-MC with 3% BSA for 2 hours, followed by three washes. Secondary antibodies diluted in PBS-MC with 3% BSA were incubated for 1 hour, followed by three washes. The slide was mounted with a No. 1.5 glass coverslip and Prolong Gold Antifade reagent (Invitrogen).

Primary antibodies for immunostaining included guinea pig anti-vGlut1 (Millipore AB590, 1:150), chicken anti-MAP2 (Abcam AB5392, 1: 100), goat anti-PSD95 (Abcam AB12093, 1:100), DA9 (1:150), and PHF1 (1:80). Fluorescent secondary donkey antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA) and used at 1:100 dilutions (anti-guinea pig DyLight 649, anti-chicken Cy3, anti-goat Alexa 488, and anti-mouse Alexa 488).

Image Acquisition and Analysis

Fluorescent and brightfield images of immunostained synaptoneurosomes were acquired using an Axio Imager Z epifluorescence microscope (Carl Zeiss AG, Oberkochen, Germany) equipped with a 63X oil immersion objective (numerical aperture, 1.40). Images were deconvoluted using the Iterative Deconvolution plug-in (by Bob Dougherty, OptiNav, Inc.) in ImageJ software (version 1.44). Synaptic protein co-localization was determined via manual analysis on randomly selected areas from wide-field images.

Transmission Electron Microscopy

Synaptoneurosome pellets were fixed in 2% glutaraldehyde and 2% paraformaldehyde in PBS overnight at 4°C, rinsed, post-fixed in 1% osmium tetroxide, and embed-
In LR White resin (Electron Microscopy Sciences, Hatfield, PA). Images were acquired using a transmission electron microscope equipped with an ATM digital camera (JEOL1011; JEOL USA, Inc., Peabody, MA).

**Data and Statistical Analyses**

Western blots were quantified via densitometry using the gel analysis function in ImageJ software (version 1.44). Statistical tests (paired t-test, Mann-Whitney test, two-way analysis of variance, and linear regression) were performed using statistical software (GraphPad version 5.03; Prism Software Corp., La Jolla, CA).

**Results**

**p-tau Oligomers Accumulate at Synapses in AD**

Proteins from control and AD cortical homogenates were extracted using 1.5% SDS and analyzed using SDS-PAGE. In total protein extracts, control brains exhibited only monomeric nonhyperphosphorylated tau (50 to 65 kDa). AD-affected brains contained tau species that were hyperphosphorylated (reactive against p-tau antibodies CP1321 and PHF122) and migrated as a smear (Figure 1). Fast-migrating species (15 to 50 kDa) represented truncated p-tau; slow-migrating species (65 to several hundred kDa) represented p-tau oligomers, which were stably misfolded and resistant to SDS denaturation and reducing agents.

To understand the subcellular localization of tau proteins in AD, we separated cortical tissue homogenates into cytosolic and synaptic (synaptoneurosome) fractions. The synaptoneurosome fraction, when examined under electron microscopy, showed well-preserved synaptic structures. In both control and AD synaptoneurosomes, no fibrillar protein aggregates were detected under electron microscopy (Figure 2A). Biochemical analysis of tau in control samples showed that nonphosphorylated tau was more enriched in the cytosol than in synaptoneurosomes, consistent with its expected primary distribution in the axonal cytoplasm. In contrast, analysis of AD samples revealed that p-tau accumulated to high levels in AD synaptoneurosomes, but remained surprisingly absent in cytosolic extracts (Figure 2B). Considered together, our data suggest that p-tau can form nonfibrillar aggregates associated with the synaptoneurosomal pellet, containing SDS-resistant oligomers.

To examine whether the p-tau oligomers observed in AD synaptoneurosomes were associated with synapses rather than originating from other contaminants...
that PSD95 and vGlut1 often seemed to be so close as to almost overlap, whereas MAP2 and vGlut1 seemed most frequently to be adjacent but distinct puncta; we, therefore, chose to use MAP2 to mark postsynaptic sites to enable more straightforward identification of the presynaptic or postsynaptic localization of other proteins including tau.

Using an antibody (DA9) that recognizes both phosphorylated and nonphosphorylated forms of tau, we detected tau in many vGlut1-positive presynaptic puncta (55.3%) and also in most MAP2-positive postsynaptic sites (70.2%) in control human brains. In AD-affected brains, we detected tau at 63.3% of presynaptic sites and 70.1% of postsynaptic sites (Figure 4, B and C). With two-way analysis of variance, we did not detect a significant difference in tau distribution between presynaptic and postsynaptic sites or between control and AD-affected brains.

Under electron microscopy, approximately 80% of the presynaptic terminals isolated from rat brains contain visible microtubules. Inasmuch as tau is an abundant microtubule-binding protein in axons, our identification of tau in 55.3% of the synapses is reasonable, and possibly an underestimate. With use of the same criteria, neighboring postsynaptic structures from control brains exhibit 70.2% tau labeling, which is consistent with recent reports that indicated which tau may also have a postsynaptic localization.

p-tau is Localized to Both Presynaptic and Postsynaptic Sites and Co-Sediments with PSD Markers

Immunocytochemistry using PHF1 antibody did not detect p-tau in control synapses, but labeled a substantial percentage of AD synapses: 20.8% of vGlut1-positive presynaptic puncta and 32.0% of MAP2-positive postsynaptic puncta (Figure 5). These data support the hypothesis that normal tau is already present at both pre- and postsynaptic sites.

A

Tau is Localized to Both Presynaptic and Postsynaptic Terminals in Control and AD-Affected Brains

Biochemical analysis did not demonstrate whether tau and p-tau were localized to presynaptic or postsynaptic terminals; therefore, we developed a new immunostaining protocol to determine this. To visualize isolated synaptic terminals, we spread a dilute solution of synaptoneurosomes onto a glass slide and fixed it lightly in place (see Materials and Methods). The fixed permeabilized synaptoneurosomes were immunostained for vesicular glutamate transporter 1 (vGlut1) as a presynaptic marker, and microtubule-associated protein 2 (MAP2) as a postsynaptic marker (Figure 4A). MAP2 is a major microtubule-binding protein in dendrites, but is also present at lower levels inside dendritic spines and at the PSD.25,26

We confirmed the postsynaptic localization of MAP2 by co-staining with PSD95 (Figure 4D), and noted such as tau inclusions, we used sucrose gradient to further purify synaptic terminals (Figure 3A). One potential concern was that large nonfibrillar tau aggregates could have co-precipitated with synaptoneurosomes during low-speed centrifugation (1000 \( \times \) g). Because large protein assemblies are more dense than lipid-rich vesicles, we chose a flotation gradient to purify synaptic terminals. Flotation gradient–purified synaptic terminals showed great reductions in organelle contaminants such as nuclei and myelin (Figure 3B). In control brains, they contained low but clearly detectable levels of nonphosphorylated monomeric tau, suggesting a synaptic localization of tau and confirming recent reports of a normal role for tau at the synapse.13,24 In AD-affected brains, they contained high levels of p-tau including aggregate species (Figure 3C), which suggested that hyperphosphorylation and oligomerization are specific to AD synapses.
synaptic and postsynaptic terminals in normal brains and that, during the pathologic progression of AD, tau misfolding and hyperphosphorylation occur on both sides of the synapse.

To understand the properties of synaptic p-tau oligomers, we extracted synaptoneurosomes using 2% Triton X-100 to solubilize membrane and free cytoplasmic proteins, and the remaining insoluble material was collected as the crude PSD pellet, which retained nearly all of the PSD95 protein and most of the actin and microtubule cytoskeleton (Figure 6). Most of the normal tau protein in control human synapses was extractable using Triton, and the small amount of tau retained in the crude PSD pellet was consistent with mouse studies that co-immunoprecipitated tau and PSD95.13 In contrast, in AD synaptoneurosomes, essentially all p-tau species remained in the Triton-insoluble pellet, indicating that they were associated with the PSD and the cytoskeleton fraction, which supports our immunostaining data that they accumulate in dendritic spines. The crude PSD pellet also exhibited an enrichment of ubiquitinated proteins and ubiquitin-binding 26S proteasomes, but not ubiquitin-nonbinding 20S proteasomes.

**p-tau Accumulation, but Not Aβ Accumulation, is Associated with Altered Protein Turnover at Synapses**

The accumulation of p-tau oligomers at AD synapses implies that the protein quality control system is overwhelmed. The primary proteolytic mechanism for both normal and abnormal proteins at the synapse is the UPS.28 To examine whether there is UPS impairment at the synapse in AD, we measured the levels of ubiquitin-protein conjugates (proteasome substrates) in total and synaptic extracts. The synaptic extracts showed significant increases in ubiquitin conjugates in AD-affected brains compared with control brains (P = 0.02; Figure 7A). This was accompanied by significant increases in synaptic 26S proteasomes and valosin-containing protein (VCP), a chaperone that delivers substrates to proteasomes (Figure 7B). The importance of VCP in the neuronal defense against misfolded proteins is reflected in its known mutations that lead to frontotemporal dementia and amyotrophic lateral sclerosis.29 The simultaneous increase in proteasome substrates, proteasomes, and related chaperones suggested reduced UPS efficiency at AD synapses.

Next, we examined the correlation between p-tau accumulation and UPS alteration in AD synaptoneurosomes. We found that p-tau oligomer levels positively correlated with ubiquitin conjugate levels (P = 0.007; Figure 8A) and proteasome levels (P = 0.02; Figure 8B), and to a lesser extent with VCP (P = 0.08; Figure 8C). Previously, we have also quantified the synaptoneurosomal enrichment of Aβ monomers and oligomers (2-3mer) in these AD cases using SDS-PAGE and immunoblotting.30 We, therefore, compared the Aβ measures previously reported from these same cases with the tau and UPS-related measures presented herein. We found that within the AD group, the levels of presumably extracellular Aβ monomers or oligomers did not correlate with the levels of intracellular ubiquitin conjugates, proteasomes, or p-tau oligomers (Figure 8, D–I). These results suggest that at AD synapses, UPS impairment and tau abnormalities may progress together; however, the involvement of Aβ species is much less clear because of lack of correlation.

**Synaptic p-tau at AD Synapses is Ubiquitinated and Interacts with the 26S Proteasome**

The co-enrichment of misfolded tau, ubiquitin conjugates, and 26S proteasomes in the crude PSD pellet
tured synaptoneurosome extracts (Figure 9A). The formed a ubiquitin pull-down experiment using denatured and capable of interacting with proteasomes, we performed ubiquitinated tau at synapses may sequester proteasomes through direct physical interaction. To verify ubiquitination of tau in AD-affected brains is ubiquitinated, we developed a new method to biochemically isolate synaptoneurosomal preparations from human brains and also to then visualize that preparation of remarkably intact synaptic structures by smearing them on a microscope slide. Both techniques suggested that tau is present at both presynaptic and postsynaptic sites and that abnormal tau dramatically accumulates at the synapse in AD.

Potential Causes of Synaptic p-tau Oligomers

Our identification of p-tau at AD synapses supports similar observations by other groups using different methods. Applying immunohistochemistry to fixed, AD-affected brains, p-tau has been observed at thorny excrescences (large spine clusters) on CA3 hippocampal dendrites. Using flow cytometry, another study found p-tau in 32.3% of AD synaptosomes, which is in agreement with our data. Finally, we noted that increased synaptionic laminar tau co-occurs with evidence of UPS dysfunction (Figures 7 and 8), which suggests the possibility that tau accumulation is related to an underlying defect in synaptic UPS capability, which may more generally contribute to the accumulation of pathologic proteins at the synapse.

Discussion

There is growing evidence that synaptic toxicity in AD may be mediated, at least in part, by smaller, more diffusible forms of misfolded Aβ and tau aggregates, generally termed “oligomers.” The objective of the present study was to examine the localization and biochemical properties of synapse-associated tau oligomers. To do so, we developed a new method to biochemically isolate synaptoneurosomal preparations from human brains and also to then visualize that preparation of remarkably intact synaptic structures by smearing them on a microscope slide. Both techniques suggested that tau is present at both presynaptic and postsynaptic terminals in AD. Oligomeric forms of tau including SDS-stable tau aggregates, likely formed from noncovalent interaction, and 33 are readily observed when AD-affected brain homogenates are extracted using SDS and analyzed via SDS-PAGE under reducing conditions. Typically, tau produces a “smear” pattern in Western blots (Figure 1). By performing subcellular fractionation before SDS extraction, we found that p-tau oligomers are also present at high levels at AD synapses (Figures 2 and 3). Immunocytochemistry experiments further revealed that p-tau accumulates in both presynaptic and postsynaptic terminals in AD (Figure 5). Finally, we noted that increased synaptionic laminar tau co-occurs with evidence of UPS dysfunction (Figures 7 and 8), which suggests the possibility that tau accumulation is related to an underlying defect in synaptic UPS capability, which may more generally contribute to the accumulation of pathologic proteins at the synapse.
that posttranslationally modified tau is transported to synaptic sites, where it accumulates. We detected normal tau in most presynaptic and postsynaptic terminals in control brains (Figure 4). We also found that synaptic p-tau aggregates are “sticky”: that is, they remain bound to PSD and cytoskeleton after Triton extraction (Figure 6). To translocate to dendritic spines, misfolded p-tau with sticky properties originating from axons or somas would have to be transported over long distances to remote confined spaces, which seems unlikely. Thus, we favor the hypothesis that tau misfolding and hyperphosphorylation occurs in situ at both presynaptic and postsynaptic structures.

This model would also imply impairment in the local degradation of tau. We further explored this possibility because the UPS has recently been shown to have a major role in degradation of both neuronal tau and synaptic components. We found evidence of accumulation of misfolded, posttranslationally modified tau (hyperphosphorylated and ubiquitinated) at synapses, with parallel increases in ubiquitinated proteins and UPS components. It is likely that tau misfolding and UPS impairment may form a vicious cycle at synapses. Misfolded ubiquitinated tau inhibits proteasomes, which in turn may inhibit the normal turnover of tau, to favor the formation of additional misfolded species.

Potential Toxic Effects of p-tau Oligomers

From study of postmortem brain tissues, it is difficult to ascertain whether p-tau oligomers are toxic to synapses. We noted, however, that numerous studies have demonstrated that misfolded, aggregation-prone proteins are toxic to neurons in general, including abnormal tau. The toxic gain-of-function of misfolded proteins is generally attributed both to the exposure of sticky, hydrophobic surfaces on the misfolded protein and to the disruption of protein quality control systems. Our present observations are consistent with both features: synaptic p-tau seems to be sticky and is associated with itself and with the PSD and cytoskeleton in a detergent-resistant fashion, and p-tau oligomers also correlate well with the accumulation of proteasome substrates. We found p-tau oligomers to be ubiquitinated and to interact directly with the ubiquitin-interacting motif of 26S proteasomes (the docking site of ubiquitinated substrates on proteasomes), potentially acting as poor substrates that impede the proteolytic enzyme. It is also conceivable that SDS-resistant oligomers at synapses can act as seeds of aggregation and spread tauopathy to other cellular compartments, or even across synapses, as implicated in animal models of tauopathy.

Synaptic tau in the Context of Other AD Lesions

The observation that misfolded tau accumulates at the synapse is reminiscent of the observation that oligomeric Aβ also seems to accumulate at the synapse. We were intrigued to find that Aβ species (both monomers and oligomers) did not correlate with p-tau accumulation or UPS impairment, whereas the latter two correlated well (Figure 8). This pattern of correlation seems to correspond to the subcellular compartmentalization of various proteins and proteolytic systems. Intracellular nonmembrane proteins such as tau are degraded by proteasomes, therefore, tau and UPS changes are expected to be correlated. In contrast, extracellular Aβ is degraded by extracellular proteases such as neprilysin and insulin-degrading enzyme, whereas intracellular Aβ is membrane associated and may, therefore, be degraded by lysosomal proteases.

Our data imply that there may be an Aβ-independent pathologic progression at AD synapses that involves both tau misfolding and UPS impairment. This parallels our earlier findings that Aβ accumulates and plateaus in the early stage of AD and that there is a lack of correlation between Aβ species and late-stage disease progression characterized by synaptic loss and NFT deposition.

In conclusion, in the present study, we devised reliable methods to detect tau proteins at human synapses, leading to the demonstration that tau is a normal postsynaptic protein in addition to its traditional localization as a presynaptic and axonal protein. In AD, we identified p-tau oligomers as a potential synaptotoxic species that accumulates in both presynaptic and postsynaptic terminals. The accumulation of abnormal tau species (misfolded, hyperphosphorylated, and ubiquitinated) parallels evidence of UPS dysfunction at the synapse. A better understanding of the subcellular localization of abnormal tau species and their properties may provide improved understanding of the molecular mechanisms of synaptic dysfunction and loss that are believed to underlie cognitive impairments in AD.

Acknowledgments

We thank Marian DiFiglia and the Philly Dake Electron Microscopy Center for access to the transmission electron microscope, Karlotta Fitch for assistance with brain tissues, and Peter Davies for anti-tau antibodies PHF1, CP13, and DA9.

References

7. Ingelsson M, Fukuimoto H, Newell KL, Growdon J, Hedley-Whyte ET, Frosch MP, Albert MS, Hyman BT, Iznirazy MC: Early Abeta accumu-